The Cooper Cos. Inc. reported a 16% year-over-year rise in fiscal fourth-quarter 2017 earnings and disclosed its guidance for fiscal year 2018.
The medical device company's non-GAAP EPS for the three-month period ended Oct. 31 amounted to $2.65, up from $2.28 in the year-ago period.
The S&P Capital IQ consensus normalized EPS estimate for the quarter was $2.65.
The company's GAAP net income attributable to Cooper stockholders totaled $88.6 million, or $1.78 per share, up from $60.5 million, or $1.23 per share, during the August-October 2016 period.
Net sales over the three-month period rose 8% year over year to $561.5 million from $518.7 million.
The company recorded research and development expense of $18.5 million during the quarter, an increase from $18 million a year ago.
For the full year ended Oct. 31, 2017, Cooper reported non-GAAP EPS of $9.70, up 15% from $8.44 in fiscal year 2016.
The S&P Capital IQ consensus normalized EPS estimate for fiscal 2017 was $9.71.
For fiscal year 2017, GAAP net attributable income rose year over year to $372.9 million, or $7.52 per share, from $273.9 million, or $5.59 per share.
Cooper forecasts non-GAAP EPS to range between $11.35 and $11.65 for the year ending Oct. 31, 2018. The company anticipates total revenue of between $2.48 billion and $2.53 billion for fiscal year 2018.